The Veterinary Medicines Directorate has completed an in‑depth assessment of Librela, an injectable pain relief for canine osteoarthritis. Published on 16 February 2026, the review concludes the benefits continue to outweigh the risks for most dogs treated. (gov.uk)
The assessment examined reports of death, faster‑than‑expected progression of arthritis and human exposure, alongside routine review of lack of efficacy, recumbency, muscle weakness, tremor and lameness. It used UK reports submitted from first authorisation through July 2025 and coded under VeDDRA. (gov.uk)
Safety information has been tightened. The VMD notes that immune‑mediated polyarthritis, paresis and paralysis were added to Librela’s product information in January 2026, with a 3 February notice also introducing a special‑precaution to use caution in patients with specified immune‑mediated conditions. (gov.uk)
Reported adverse events are currently classified as uncommon, estimated at 1 to 10 animals per 1,000 treated. Reports of death are rare, at 1 to 10 animals per 10,000 treated. Use is typically in older dogs with co‑morbidities, complicating causal attribution. (gov.uk)
Librela contains bedinvetmab, a monoclonal antibody indicated for pain associated with osteoarthritis. The VMD’s analysis reiterates that, on available evidence, the overall benefit–risk balance remains positive when the medicine is used as authorised. (gov.uk)
Prescribers are advised to consult the current Summary of Product Characteristics before use, monitor patients during treatment and report suspected adverse events promptly to the Marketing Authorisation Holder, Zoetis. The Directorate will write to veterinary professionals with fuller findings and approved text changes. (gov.uk)
For owners, the message is straightforward: discuss any concerns with your vet, read the product information leaflet and, if a dog appears unwell after injection, seek veterinary advice without delay. (gov.uk)
The reporting framework is restated. The Marketing Authorisation Holder must maintain systems to collect and evaluate adverse event information and report to the VMD within 30 days of awareness, with detailed case data and imaging encouraged to support robust assessment. (gov.uk)
The updated SPCs are available via the VMD Product Information Database, the definitive record for GB and NI. The regulator notes database text updates appear quickly but changes may take up to 12 months to reach packaged leaflets in the market. (vmd.defra.gov.uk)
Librela was first authorised in November 2020 and remains a prescription‑only veterinary medicine. Future clinically significant safety updates and SPC changes will be signposted on GOV.UK under urgent safety updates for veterinary medicines. (vmd.defra.gov.uk)